A Safety and Efficacy Study of SHR4640 and Febuxostat in Subjects With Hyperuricemia

NCT04180982 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

84

Enrollment

INDUSTRY

Sponsor class

Conditions

Hyperuricemia

Interventions

DRUG: SHR4640 dose1 plus Febuxostat dose1
DRUG: SHR4640 dose1 plus Febuxostat dose2
DRUG: SHR4640 dose2 plus Febuxostat dose3

Sponsor

Jiangsu HengRui Medicine Co., Ltd.